- CDC. 1998 Guidelines for treatment of sexually transmitted
diseases. MMWR 1998;47(No. RR-1).
- CDC. Hepatitis B virus: a comprehensive strategy for
eliminating transmission in the United States through universal
childhood vaccination---recommendations of the Immunization
Practices Advisory Committee (ACIP). MMWR 1991;40(No. RR-13).
- CDC. Prevention of hepatitis A through active or passive
immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR 1999;48(No. RR-12).
- Hatcher RA, Trussell TJ, Stewart FH, et al., eds.
Contraceptive technology. 17th ed. New York: Ardent
Media, 1998.
- Drew WL, Blair M, Miner RC, Conant M. Evaluation
of the virus permeability of a new condom for women. Sex Transm Dis
1990;17:110--2.
- Richardson BA. Nonoxynol-9 as a vaginal
mircrobicide for prevention of sexually transmitted infections. JAMA
2002;287:1171--2.
- Cates W, Stone KM. Family planning, sexually
transmitted diseases, and contraceptive choice: a literature
update---part I. Fam Plann Perspectives 1992;24:74--84.
- CDC. Revised guidelines for HIV counseling, testing, and
referral and revised recommendations for HIV screening of pregnant
women. MMWR 2001;50(No. RR-19):13--26.
- Kamb ML, Fishbein M, Douglas JM, et al. HIV
prevention counseling reduces high risk behaviors and sexually
transmitted diseases: results from a multicenter, randomized
controlled trial (Project RESPECT). JAMA 1998;280:1161--7.
- U.S. Preventive Services Task Force. Guide to
clinical preventive services. 2nd ed. Baltimore, MD:
Williams & Wilkins, 1996.
- American Academy of Pediatrics and American
College of Obstetricians and Gynecologists. Guidelines for perinatal
care. 4th ed. Washington, DC: American Academy of
Pediatrics and American College of Obstetricians and Gynecologists,
1997.
- American College of Obstetricians and
Gynecologists. Antimicrobial therapy for obstetric patients.
Washington, DC: American College of Obstetricians and Gynecologists,
March 1998. (Educational bulletin, no. 245.)
- American College of Obstetricians and
Gynecologists. Committee opinion: primary and preventive care.
Washington, DC: American College of Obstetricians and Gynecologists,
December 1999. (Periodic assessments, no. 229.)
- CDC. Recommendations for the prevention and management of
Chlamydia trachomatis infections, 1993. MMWR 1993;42(No.
RR-12).
- Zanetti AR, Tanzi E, Newell ML. Mother-to-infant
transmission of hepatitis C virus. J Hepatol 1999;31(Suppl):96--100.
- Burns DN, Minkoff H. Hepatitis C: screening in
pregnancy. Obstet Gynecol 1999;94:1044.
- American College of Obstetricians and
Gynecologists. Viral hepatitis in pregnancy. Washington, DC:
American College of Obstetricians and Gynecologists, July 1998.
(Educational bulletin, no. 248.)
- American Academy of Pediatrics and American
College of Obstetricians and Gynecologists. Human immunodeficiency
virus screening: joint statement of the AAP and ACOG. Pediatrics
1999;104:128.
- Institute of Medicine. Reducing the odds:
preventing perinatal transmission of HIV in the United States.
Washington, DC: National Academy Press, 1999.
- CDC. Revised US Public Health Service recommendations for
human immunodeficiency virus screening of pregnant women. MMWR
2001;50(No. RR-19):59--86.
- CDC. USPHS/IDSA Prevention of Opportunistic
Infections Working Group. 2001 USPHS/IDSA guidelines for the
prevention of opportunistic infections in persons infected with
human immunodeficiency virus. Atlanta, GA: US Department of Health
and Human Services, Centers for Disease Control and Prevention,
November 28, 2001. Available at http://www.hivatis.org.
- CDC. Testing for antibodies to human
immunodeficiency virus type 2 in the United States. MMWR (in press).
- Department of Health and Human Services, Henry
J. Kaiser Foundation Panel on Clinical Practices for the Treatment
of HIV Infection. Guidelines for the use of antiretroviral agents in
HIV-infected adults and adolescents. US Department of Health and
Human Services, February 4, 2002. Available at http://www.hivatis.org.
- Carpenter CJ, Cooper DA, Fischl MA, et al.
Antiretroviral therapy in adults: updated recommendations of the
International AIDS Society---USA Panel. JAMA 2000;283:381--90.
- CDC. CDC National Prevention Plan. Federal
Register 2002 (in press).
- CDC. Prevention and treatment of tuberculosis among
patients infected with human immunodeficiency virus: principles of
therapy and revised recommendations. MMWR 1998;47(No. RR-20).
- CDC. HIV Prevention case management: guidance.
Atlanta, GA: US Department of Health and Human Services, Public
Health Service, September 1997.
- Fowler MG, Simonds RJ, Roongpisuthipong A.
Update on perinatal HIV transmission. Pediatr Clin North Am
2000;47:241--60.
- CDC. Recommendations for the use of
antiretroviral drugs in pregnant HIV-1 infected women for maternal
health and interventions to reduce perinatal HIV-1 transmission in
the United States. Atlanta, GA: US Department of Health and Human
Services, February 4, 2002. Available at http://www.hivatis.org.
- CDC. Guidelines for the use of antiretroviral
agents in pediatric HIV infection. Atlanta, GA: US Department of
Health and Human Services, August 8, 2001. Available at http://www.hivatis.org.
- Wald A. New therapies and prevention strategies
for genital herpes. Clin Infect Dis 1999;28(Suppl):S4--S13.
- Bodsworth NJ, Crooks RJ, Borelli S, et al.
Valaciclovir versus acyclovir in patient-initiated treatment of
genital herpes: a randomized, double-blind clinical trial.
Genitourin Med 1997;73:110--6.
- Patel R, Bodsworth NJ, Wooley P, et al.
Valaciclovir for the suppression of recurrent genital HSV infection:
a placebo controlled study of once-daily therapy. Genitourin Med
1997;73:105--9.
- Spruance S, Trying S, Degregorio B, Miller C,
Beutner K, the Valaciclovir HSV Study Group. A large-scale,
placebo-controlled, dose-ranging trial of peroral valacyclovir for
episodic treatment of recurrent herpes genitalis. Arch Int Med
1996;156:1729--35.
- Fife KH, Barbarash RA, Rudolph T, Degregorio B,
Roth RE. Valaciclovir versus acyclovir in the treatment of
first-episode genital herpes infection: results of an international,
multicenter, double-blind randomized clinical trial. Sex Transm Dis
1997;24:481--6.
- Reitano M, Tyring S, Lang W, et al. Valaciclovir
for the suppression of recurrent genital herpes simplex virus
infection: a large-scale dose range-finding study. J Infect Dis
1998;178:603--10.
- Chosidow O, Drouault Y, Lecontae-Veyriac F, et
al. Famciclovir vs. aciclovir in immunocompetent patients with
recurrent genital herpes infections: a parallel-groups, randomized,
double-blind clinical trial. Br J Dermatol 2001:144:818--24.
- Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R,
Saltzman RL. Oral famciclovir for the suppression of recurrent
genital herpes: a randomized controlled trial. JAMA
1998;280:887--92.
- Loveless M, Harris W, Sacks S. Treatment of
first episode genital herpes with famciclovir. In: Programs and
abstracts of the 35th Interscience Conference on Antimicrobial
Agents and Chemotherapy, San Francisco, California, 1995.
- Mertz GJ, Loveless MO, Levin MJ, et al. Oral
famciclovir for suppression of recurrent genital herpes simplex
virus infection in women: a multicenter, double-blind,
placebo-controlled trial. Arch Intern Med 1997;157:343--9.
- Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J,
Shafran SD. Patient-initiated, twice-daily oral famciclovir for
early recurrent genital herpes: a randomized, double-blind
multicenter trial. JAMA 1996;276:44--9.
- Henry RE, Wegmann JA, Hartle JE, Christopher GW.
Successful oral acyclovir desensitization. Ann Allergy
1993;70:386--8.
- Reiff-Eldridge RA, Heffner CR, Ephross SA,
Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after
prenatal drug exposure through prospective pregnancy registries: a
pharmaceutical company commitment. Am J Obstet Gynecol
2000;182:159--63.
- Scott LL, Sanchez PJ, Jackson GL, Zeray F,
Wendel GD, Jr. Acyclovir suppression to prevent cesarean delivery
after first-episode genital herpes. Obstet Gynecol 1996;87:69--73.
- Brocklehurst P, Kinghorn G, Carney O, et al. A
randomised placebo controlled trial of suppressive acylovir in late
pregnancy in women with recurrent genital herpes infection. Br J
Obstet Gynaecol 1998;105:275--80.
- Thorpe EM, Stamm WE, Hook EW, et al. Chlamydial
cervicitis and urethritis: single dose treatment compared with
doxycycline for seven days in community-based practices. Genitourin
Med 1996;72:93--7.
- Stamm WE, Hicks CB, Martin DH, et al.
Azithromycin for empirical treatment of the nongonococcal urethritis
syndrome in men: a randomized double-blind study. JAMA
1995;274:545--9.
- Adair CD, Gunter M, Stovall TG, McElvoy G,
Veille JC, Erment JM. Chlamydia in pregnancy: a randomized trial of
azithromycin and erithromycin. Obstet Gynecol 1998;91:165--8.
- Wehbeh HA, Ruggeirio RM, Shakem S, Lopez G, Ali
Y. Single dose azithromycin for chlamydia in pregnant women. J
Reprod Med 1998;43:509--14.
- Moran JS, Levine WC. Drugs of choice for the
treatment of uncomplicated gonococcal infections. Clin Infect Dis
1995;20(Suppl 1);S47--S65.
- Haimovici R, Roussel TJ. Treatment of gonococcal
conjunctivitis with single-dose intramuscular ceftriaxone. Am J
Ophthalmol 1989;107:511--4.
- Hauth JC, Goldenberg RL, Andrews WW, DuBard MB,
Copper RL. Reduced incidence of preterm delivery with metronidazole
and erythromycin in women with bacterial vaginosis. N Engl J Med
1995;333:1732--6.
- Morales WJ, Schorr S, Albritton J. Effect of
metronidazole in patients with preterm birth in preceding pregnancy
and bacterial vaginosis: a placebo-controlled, double-blind study.
Am J Obstet Gynecol 1994;171:345--9.
- McDonald HM, O'Loughlin JA, Vigneswaran R, et
al. Impact of metronidazole therapy on preterm birth in women with
bacterial vaginosis flora (Gardnerella vaginalis): a
randomised, placebo controlled trial. Br J Obstet Gynaecol
1997;104:1391--7.
- Jackson P, Ridley WJ, Pattison NS. Single dose
metronidazole prophylaxis in gynaecological surgery. NZ Med J
1979;89:243--5.
- Willis AT. Metronidazole in the prevention and
treatment of Bacteroides infections in gynaecological patients.
Lancet 1974;2:1540--3.
- Persson E, Bergstrom M, Larsson PG, et al.
Infections after hysterectomy: a prospective nationwide Swedish
Study. Acta Obstetrica et Gynecologiaca Scandinavica
1996;75:757--61.
- Larsson PG, Platz-Christensen JJ, Forsum U,
Pahlson C. Clue cells in predicting infections after abdominal
hysterectomy. Obstet Gynecol 1991;77:450--2.
- Newton ER, Prihoda TJ, Gibbs RS. A clinical and
microbiologic analysis of risk factors for puerperal endometritis.
Obstet Gynecol 1990;75:402--6.
- Soper DE, Bump RC, Hurt WG. Bacterial vaginosis
and trichomoniasis vaginitis are risk factors for cuff cellulitis
after abdominal hysterectomy. Am J Obstet Gynecol 1990;163:1016--21.
- Watts DH, Krohn MA, Hillier SL, Eschenbach DA.
Bacterial vaginosis as a risk factor for post-cesarean endometritis.
Obstet Gynecol 1990;75:52--8.
- Silver HM, Sperling RS, St. Clair PJ, Gibbs RS.
Evidence relating bacterial vaginosis to intraamniotic infection. Am
J Obstet Gynecol 1989;161:808--12.
- Bjornerem A, Aghajani E, Maltau JM, Moi H.
Occurrence of bacterial vaginosis among abortion seekers. Tidsskrift
for Den Norske Laegeforening 1997;117:1282--4.
- Hamark B, Forssman L. Postabortal endometritis
in chlamydia-negative women---association with preoperative clinical
signs of infection. Gynecol Obstet Invest 1991;31:102--5.
- Larsson PG, Bergman B, Forsum U, Platz-Christensen
JJ, Pahlson C. Mobiluncus and clue cells as predictors of PID after
first-trimester abortion. Acta Obstetrica et Gynecologica
Scandinavica 1989;68:217--20.
- Hillier SL, Martius J, Krohn M, Kiviat N, Holmes
KK, Eschenbach DA. A case-control study of chorioamnionic infection
and histologic chorioamnionitis in prematurity. New Engl J Med
1998;319:972--8.
- Livengood CH, III, Soper DE, Sheehan KL, et al.
Comparison of once-daily and twice-daily dosing of 0.75%
metronidazole gel in the treatment of bacterial vaginosis. Sex
Transm Dis 1999;26:137--42.
- Sobel J, Peipert JF, McGregor JA, et al.
Efficacy of clindamycin vaginal ovule vs. clindamycin vaginal cream
in bacterial vaginosis. Infect Dis Obstet Gynecol 2002 (in press).
- Moi H, Erkkola R, Jerve F, et al. Should male
consorts of women with bacterial vaginosis be treated? Genitourin
Med 1989;65:263--8.
- Colli E, Landoni M, Parazzini F, et al.
Treatment of male partners and recurrence of bacterial vaginosis: a
randomised trial. Genitourin Med 1997;73:267--70.
- Vejtorp M, Bollerup AC, Vejtorp L, et al.
Bacterial vaginosis: a double-blind randomized trial of the effect
of treatment of the sexual partner. Br J Obstet Gynaecol
1988;95:920--6.
- McGregor JA, French JI, Jones W, et al.
Bacterial vaginosis is associated with prematurity and vaginal fluid
mucinase and sialidase: results of a controlled trial of topical
clindamycin cream. Am J Obstet Gynecol 1994;170:1048--59.
- Joesoef MR, Hillier SL, Wiknjosastro G, et al.
Intravaginal clindamycin treatment for bacterial vaginosis: effects
on preterm delivery and low birth weight. Am J Obstet Gynecol
1995;173:1527--31.
- Vermeulen GM, Bruinse HW. Prophylactic
administration of clindamycin 2% vaginal cream to reduce the
incidence of spontaneous preterm birth in women with an increased
recurrence risk: a randomised placebo-controlled double-blind trial.
Br J Obstet Gynaecol 1999;106:652--7.
- Caro-Paton T, Carvajal A, Martin de Diego I,
Martin-Arias LH, Alvarez Requejo A. Is metronidazole teratogenic? A
meta-analysis. Br J Clin Pharmacol 1997;44:179--82.
- Burtin P, Taddio A, Ariburnu O, Einarson TR,
Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J
Obstet Gynecol 1995;172:525--9.
- Piper JM, Mitchel EF, Ray WA. Prenatal use of
metronidazole and birth defects: no association. Obstet Gynecol
1993;82:348--52.
- Carey JC, Klebanoff MA, Hauth JC, et al.
Metronidazole to prevent preterm delivery in pregnant women with
asymptomatic bacterial vaginosis. New Engl J Med 2000;342:534--40.
- Hay PE, Ugwumadu AHN, Jeffrey I, Manvonda JT.
Oral clindamycin prevents spontaneous preterm birth and mid
trimester miscarriage in pregnant women with bacterial vaginosis.
Int J STD AIDS 2001;12(Suppl 2):70--1.
- Pearlman MD, Yashar C, Ernst S, Solomon W. An
incremental dosing protocol for women with severe vaginal
trichomoniasis and adverse reactions to metronidazole. Am J Obstet
Gynecol 1996;174:934--6.
- Klebanoff MA, Carey JC, Hauth JC, et al. Failure
of metronidazole to prevent preterm delivery among pregnant women
with asymptomatic Trichomonas vaginalis infection. New Engl J
Med 2001;345:487--93.
- Walker CK, Kahn JG, Washington AE, Peterson HB,
Sweet RL. Pelvic inflammatory disease: meta-analysis of
antimicrobial regimen efficacy. J Infect Dis 1993;168:969--78.
- Matsuda S. Clinical study of levofloxacin (LVFX)
on the infectious diseases in the field of obstetrics and
gynecology. Chemotherapy 1992;40:311--23.
- Martens MG, Gordon S, Yarborough DR, Faro S,
Binder D, Berkeley A. Multicenter randomized trial of ofloxacin
versus cefoxitin and doxycycline in outpatient treatment of pelvic
inflammatory disease. South Med J 1993;86:604--10.
- Peipert JF, Sweet RL, Kahn J, Reilly-Gauvin K.
Evaluation of ofloxacin in the treatment of laparoscopically
documented acute pelvic inflammatory disease (salpingitis). Infect
Dis Obstet Gynecol 1999;7:138--44.
- Walker CK, Workowski KA, Washington AE, Soper D,
Sweet RL. Anaerobes in pelvic inflammatory disease: implications for
the Centers for Disease Control and Prevention's guidelines for
treatment of sexually transmitted diseases. Clin Infect Dis
1999;28(Suppl 1):S29--S36.
- Witte EH, Peters AA, Smit IB, van der Linden MC,
Mouton RP, van der Meer JW, van Erp EJ. A comparison of pefloxacin/metronidazole
and doxycycline/metronidazole in the treatment of laparoscopically
confirmed acute pelvic inflammatory disease. Eur J Obstet Gynecol
Reprod Biol 1993;50:153--8.
- Ridgway GL, Bevan C, Siddle N. Azithromycin with
or without metronidazole compared with cefoxitin, doxycycline and
metronidazole in the treatment of laparoscopy confirmed acute pelvic
inflammatory disease [Abstract]. In: Proceedings of the 11th
International Meeting of the International Society for STD Research,
New Orleans. Fort Lee, New Jersey: International Society for STD
Research, 1995.
- Cohen CR, Sinei S, Reilly M, et al. Effect of
human immunodeficiency virus type 1 infection upon acute salpingitis:
a laparoscopic study. J Infect Dis 1998;178:1352--8.
- Bukesi EA, Cohen CR, Stevens CE, et al. Effects
of human immunodeficiency virus 1 infection on microbial origins of
pelvic inflammatory disease and on efficacy of ambulatory oral
therapy. Am J Obstet Gynecol 1999;18:1374--81.
- Irwin KL, Moorman AC, O'Sullivan MJ, et al.
Influence of human immunodeficiency virus infection on pelvic
inflammatory disease. Obstet Gynecol 2000;95:525--34.
- Kamb ML. Cervical cancer screening of women
attending sexually transmitted diseases clinics. Clin Infect Dis
1995;20(Suppl 1): S98--S103.
- American Cancer Society. Guidelines for the
cancer related checkup. Atlanta, Georgia: American Cancer Society,
1998.
- American College of Obstetricians and
Gynecologists. Routine cancer screening: committee opinion 185.
Washington, DC: American College of Obstetricians and Gynecologists,
1997.
- National Cancer Institute Workshop. The 1988
Bethesda System for reporting cervical/vaginal cytological
diagnoses. JAMA 1989;262:931--4.
- Jay N, Moscicki AB. Human papillomavirus
infections in women with HIV disease: prevalence, risk, and
management [Review]. AIDS Reader 2000;10:659--68.
- Kurman RJ, Henson DE, Herbst AL, Noller KL,
Schiffman MH, National Cancer Institute Workshop. Interim guidelines
for management of abnormal cervical cytology. JAMA 1994;271:1866--9.
- MacKellar DA, Valleroy LA, Secura GM, et al. Two
decades after vaccine license: hepatitis B immunization and
infection among young men who have sex with men. Am J Public Health
2001;91:965--71.
- CDC. Immunization of adolescents: recommendations of the
Advisory Committee on Immunization Practices, the American Academy
of Pediatrics, the American Academy of Family Physicians, and the
American Medical Association. MMWR 1996;45:1--5.
- Mast EE, Williams IT, Alter MJ, Margolis HS.
Hepatitis B vaccination of adolescent and adult high-risk groups in
the United States. Vaccine 1998;16(Suppl):S27--S29.
- Alter MJ, Kruszon-Moran D, Nainan OV, et al.
The prevalence of hepatitis C virus infection in the United States,
1988 through 1994. N Engl J Med 1999;341:556--62.
- CDC. Recommendations for prevention and control of
hepatitis C virus (HCV) infection and HCV-related chronic disease.
MMWR 1998;47(No.RR-19):1--39.
- Diegstag JL. Sexual and perinatal transmission
of hepatitis C. Hepatology 1997:26(Suppl 1):S66--S70.
- Alter MJ. Epidemiology of hepatitis C.
Hepatology 1999;26(Suppl 1):S25--S65.
- Thomas DL, Zenilman JM, Alter MJ, et al. Sexual
transmission of hepatitis C virus among patients attending Baltimore
sexually transmitted disease clinics: an analysis of 309 sex
partnerships. J Infect Dis 1995;171:768--75.
- Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ.
Virus load and risk of heterosexual transmission of human
immunodeficiency virus and hepatitis C virus by men with hemophilia:
the Multicenter Hemophilia Cohort Study. J Infect Dis
2000;181:1475--8.
- Bamberger JD, Waldo CR, Gerberding JL, Katz MH.
Postexposure prophylaxis for human immunodeficiency virus (HIV)
infection following sexual assault. Am J Med 1999;106:323--6.
- CDC. Public Health Service guidelines for the management
of health care worker exposures to HIV and recommendations for
post-exposure prophylaxis. MMWR 1998;47(No. RR-7):1--33.
- American Academy of Pediatrics. Sexually
transmitted disease in adolescents and children. In: Pickering LK,
ed. 2000 Red book: report of the Committee on Infectious Diseases.
25th ed. Elk Grove Village, IL: American Academy of
Pediatrics, 2000:138--47.
- American Academy of Pediatrics Committee on
Child Abuse and Neglect. Guidelines for the evaluation of sexual
abuse of children: subject review. Pediatrics 1999;103:186--91.
- Adams JA, Harper K, Krudson S. A proposed
system for the classifications of anogenital findings in children
with suspected child abuse. Adolesc Pediatr Gynecol 1992;5:73--5.
- Shapiro RA, Schubert CJ, Siegel R. Neisseria
gonorrhoeae infections in girls younger than 12 years of age
evaluated for vaginitis. Pediatrics 1999;104:(e72):1--11.
- Lagerberg D. Sexually transmitted diseases in
children: a serious consequence of sexual abuse and an indication of
possible victimization of other children. Acta Pediatrica
1998;87:1214--7.
- Dominguez KL, Simonds RJ. Postexposure
prophylaxis. In: Zeichner SL, Read JS, eds. Handbook of pediatric
HIV care. Philadelphia: Lippincott Williams & Wilkins,
1999:294--318.
Abbreviations Used
in This Publication
ACIP |
Advisory Committee on Immunization Practices |
ACOG |
American College of Obstetricians and Gynecologists |
ACS |
American Cancer Society |
AIDS |
Acquired immunodeficiency syndrome |
ALT |
Alanine aminotransferase |
anti-HBc |
Antibody to the hepatitis B core antigen |
ASCUS |
Atypical squamous cells of undetermined significance |
BCA |
Bichloroacetic acid |
BV |
Bacterial vaginosis |
CBC |
Complete blood count |
CDC |
Centers for Disease Control and Prevention |
CI |
Confidence interval |
CIN |
Cervical intraepithelial neoplasia |
CLD |
Chronic liver disease |
CMV |
Cytomegalovirus |
CNS |
Central nervous system |
CSF |
Cerebrospinal fluid |
d4T |
Stavudine |
ddC |
Dideoxycytodine |
ddI |
Didanosine |
DFA |
Direct fluorescent antibody |
DGI |
Disseminated gonococcal infection |
dL |
Deciliter |
DNA |
Deoxyribonucleic acid |
EIA |
Enzyme immunoassay |
ELISA |
Enzyme-linked immunosorbent assay |
FDA |
Food and Drug Administration |
FTA-ABS |
Fluorescent treponemal antibody absorbed |
gG |
glycoprotein G |
GISP |
Gonococcal Isolate Surveillance Project |
HAV |
Hepatitis A virus |
HBIG |
Hepatitis B immune globulin |
HBsAg |
Hepatitis B surface antigen |
HBV |
Hepatitis B virus |
HCV |
Hepatitis C virus |
HIV |
Human immunodeficiency virus |
HPV |
Human papillomavirus |
HSV |
Herpes simplex virus |
HTLV-1 |
Human T-cell lymphotrophic virus type I |
IDV |
Indinavir |
IDU |
Injection drug user |
IFA |
Immunofluorescence assay |
IgE |
Immunoglobulin E |
Ig |
Immune globulin |
IgG |
Immunoglobulin G |
IHPS |
Infantile hypertrophic pyloric stenosis |
IM |
Intramuscularly |
IV |
Intravenous or intravenously |
kg |
Kilogram |
KOH |
Potassium hydroxide |
LGV |
Lymphogranuloma venereum |
MAC |
Mycobacterium avium complex |
mg |
Milligram |
MIC |
Minimum inhibitory concentration |
MMWR |
Morbidity and Mortality Weekly Report |
MPC |
Mucopurulent cervicitis |
MRL |
Microbiology Reference Library |
MSM |
Men who have sex with men |
N-9 |
Nonoxynol-9 |
NAAT |
Nucleic acid amplification test |
NGU |
Nongonococcal urethritis |
OTC |
Over-the-counter |
Pap |
Papanicolaou |
PCP |
Pneumocystis carinii pneumonia |
PCR |
Polymerase chain reaction |
PEP |
Postexposure prophylaxis |
PID |
Pelvic inflammatory disease |
PPD |
Purified protein derivative |
PPV |
Positive predictive value |
QRNG |
Quinolone resistant Neisseria gonorrhoeae |
RIBA |
Recombinant immunoblot assay |
RNA |
Ribonucleic acid |
RPR |
Rapid plasma reagin |
RT-PCR |
Reverse transcriptase polymerase chain reaction |
RVVC |
Recurrent vulvovaginal candidiasis |
SAQ |
Saquinavir |
SIL |
Squamous intraepithelial lesion |
STD |
Sexually transmitted disease |
TB |
Tuberculosis |
TCA |
Trichloroacetic acid |
TE |
Toxoplasmic encephalitis |
TMP-SMX |
Trimethoprim-sulfamethoxazole |
TP-PA |
Treponema pallidum particle agglutation |
TST |
Tuberculin skin test |
VDRL |
Venereal Disease Research Laboratory |
VFC |
Vaccines for children |
VVC |
Vulvovaginal candidiasis |
WB |
Western blot |
WBC |
White blood count |
ZDV |
Zidovudine |
3TC |
Lamivudine |
Chairpersons: David Atkins, M.D., M.P.H., Agency for Healthcare
Research and Quality, Rockville, MD; Kimberly A. Workowski, M.D.,
Division of STD Prevention, CDC and Emory University, Atlanta, GA.
Presenters: Adaora A. Adimora, M.D., M.P.H., University of North
Carolina, Chapel Hill, NC; Michael H. Augenbraun, M.D., State University
of New York (SUNY) Health Science Center, Brooklyn, NY; Willard Cates,
Jr., M.D., M.P.H., Family Health International, Research Triangle Park,
NC; Jane Cecil, M.D., Johns Hopkins, Baltimore, MD; Lynne Fukumoto, UCLA
School of Nursing, Los Angeles, CA; Margaret Hammerschlag, M.D., SUNY
Health Science Center, Brooklyn, NY; Anne M. Rompalo, M.D., Johns
Hopkins University, Baltimore, MD; Richard Rothenberg, M.D., Emory
University School of Medicine, Atlanta, GA; Pablo J. Sanchez, M.D.,
University of Texas Southwestern Medical Center, Dallas, TX; Bradley
Stoner, M.D., Ph.D., Washington University School of Medicine, St.
Louis, MO; Jane R. Schwebke, M.D., Department of Medicine, University of
Alabama, Birmingham, AL; Anna Wald, M.D., M.P.H., University of
Washington, Seattle, WA; Cheryl K. Walker, M.D., Stanford University
Medical Center, Stanford, CA; George D. Wendel, M.D., University of
Texas Southwestern Medical Center, Dallas, TX; Karen Wendel, M.D., Johns
Hopkins University, Baltimore, MD; Dorothy J. Wiley, Ph.D., UCLA School
of Nursing, Los Angeles, CA; Jonathan M. Zenilman, M.D., Johns Hopkins
University, Baltimore, MD. Moderators: King K. Holmes, M.D.,
Ph.D., Center for AIDS and STDs, University of Washington, Seattle, WA;
Edward W. Hook, III, M.D., University of Alabama, School of Medicine,
Birmingham, AL; William McCormack, M.D., SUNY Health Science Center,
Brooklyn, NY. Rapporteurs: John M. Douglas, Jr., M.D., Denver
Department of Public Health and University of Colorado Health Science
Center, Denver, CO; H. Hunter Handsfield, M.D., University of Washington
and Public Health-Seattle & King County, Seattle, WA; Walter Stamm,
M.D., University of Washington Medical Center, Seattle, WA.
Consultants: Gail Bolan, M.D., California Dept. of Health,
Berkeley, CA; Toye H. Brewer, M.D., University of Miami, Miami, FL;
Virginia A. Caine, M.D., Indiana University School of Medicine,
Indianapolis, MN; Connie Celum, M.D., M.P.H., University of Washington,
Seattle, WA; Myron S. Cohen, M.D., University of North Carolina, Chapel
Hill, NC; Thomas A. Farley, M.D., M.P.H., Tulane University School of
Public Health and Tropical Medicine, New Orleans, LA; Laura T. Gutman,
M.D., Duke University, Durham, NC; Penelope J. Hitchcock, D.V.M., M.S.,
National Institute for Allergy and Infectious Diseases, NIH, Bethesda,
MD; Sharon Hillier, Ph.D, Magee Women’s Hospital, Pittsburgh, PA;
Franklyn N. Judson, M.D., Denver Department of Health, Denver, CO; David
Martin, M.D., LSU Medical Center, New Orleans, LA; Daniel M. Musher,
M.D., Veterans Affairs Medical Center, Houston, TX; Newton G. Osborne,
M.D., M.P.H., Howard University Hospital, Washington, DC; Jeff Peipert,
M.D., M.P.H., Women and Infants Hospital, Providence, RI; Peter Rice,
M.D., Boston Medical Center, Boston, MA; Mary Sawyer, M.D., Emory
University, Atlanta, GA; Jack Sobel, M.D., Wayne State University,
Detroit, MI; David Soper, M.D., Medical University of South Carolina,
Charleston, SC; Lawrence R. Stanberry, M.D., Ph.D., University of Texas
Medical Branch, Galveston, TX; Barbara Stoll, M.D., Emory University
School of Medicine, Atlanta, GA; Richard Sweet, M.D., Magee Women’s
Hospital, Pittsburgh, PA; Eugene Washington, M.D., UCSF/Mt. Zion Medical
Center, San Francisco, CA; Heather Watts, M.D., National Institutes of
Health, Bethesda, MD.
Liaison Participants: Vagan A. Akovbian, M.D., Ph.D., Russian
Ministry of Health Central Institute, Moscow, Russia; Gale Burstein,
M.D., M.P.H, American Academy of Pediatrics; Willa Brown, M.D., M.P.H.,
American College of Preventative Medicine; Mike Catchpole, M.D., PHLS
Communicable Disease Surveillance, England; Tom Cox, M.D., American
Social Health Association; William Dumas, R.N., National Coalition of
STD Directors; Antonio C. Gerbase, M.D., World Health Organization;
Sharon Hillier, Ph.D., Infectious Disease Society of Obstetrics and
Gynecology; Louella Klein, M.D., American College of Obstetrics and
Gynecology; David J. Magid, M.D., M.P.H, Managed Care Colorado; Rafael
Mazin, M.D., Pan American Health Organization; Gregory J. Moran, M.D.,
American College of Emergency Physicians; Donna Richmond, M.P.H., R.N.,
Association of Reproductive Health Professionals; Anthony Schaeffer,
M.D., American Urological Association; Felicia Stewart, M.D., American
Social Health Association; Stephen K. Tyring, M.D., Ph.D., American
Academy of Dermatology; Leonard B. Weiner, M.D., American Academy of
Pediatrics; Tom Wong, M.D., M.P.H., Health Canada.
CDC/Division of STD Prevention (DSTDP)/STD Treatment Guidelines 2002
Project Coordinators: Kimberly A. Workowski, M.D., DSTDP; William C.
Levine, M.D., M.Sc., DSTDP. |